Vivek Jain Increases ICUI Stake with 21,929-Share Purchase
Rhea-AI Filing Summary
Vivek Jain, Chairman and CEO of ICU Medical, Inc. (ICUI), reported purchases of company common stock on 08/14/2025. He acquired 2,378 shares at a weighted-average price of $112.1165 (purchases ranged $111.75–$112.435) and 19,551 shares at a weighted-average price of $112.9232 (purchases ranged $112.48–$113.435). Following these transactions, Mr. Jain beneficially owns 130,149 shares directly and 88,698 shares indirectly through a trust; a prior direct holding of 110,598 shares is shown prior to the second reported purchase line. The Form 4 was signed by an attorney-in-fact, Paula Darbyshire.
Positive
- CEO increased direct ownership through open-market purchases totaling 21,929 shares on 08/14/2025
- Transparent pricing disclosed with weighted-average prices and stated per-trade ranges ($111.75–$113.435)
- Filing shows compliance with Section 16 reporting and includes attorney-in-fact signature
Negative
- None.
Insights
TL;DR: CEO purchases increased direct ownership, signaling management's capital deployment into company stock without disclosed disposition.
The report documents open-market purchases by the Chairman and CEO totaling 21,929 shares on a single date at weighted-average prices in the low $112 range. Such insider purchases are a concrete, non-speculative data point showing executive market activity and a modest increase in direct holdings to 130,149 shares. The filing includes weighted-average price ranges and an undertaking to provide per-trade details on request, which helps validate execution transparency. No derivative transactions or dispositions are reported.
TL;DR: The CEO's purchases are disclosed properly on Form 4 and increase his direct stake, with filings executed by an attorney-in-fact.
The Form 4 shows compliance with Section 16 reporting: transaction codes, weighted-average prices, and an explicit statement that multiple trades compose each line. Beneficial ownership is itemized as direct and indirect (trust). The use of an attorney-in-fact to sign is documented, which is common for timely reporting. The filing contains no indications of departures, pledges, or option exercises.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 2,378 | $112.1165 | $267K |
| Purchase | Common Stock | 19,551 | $112.9232 | $2.21M |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $111.75 to $112.435 inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $112.48 to $113.435, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.
